home / stock / mycof / mycof news

MYCOF News and Press, New Age Brands From 12/12/22

Stock Information
Company Name: New Age Brands
Stock Symbol: MYCOF
Market: OTC
Website: mydecine.com
Menu
MYCOF MYCOF Quote MYCOF Short MYCOF News MYCOF Articles MYCOF Message Board
Get MYCOF Alerts

News, Short Squeeze, Breakout and More Instantly...
MYCOF - Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address add...
MYCOF - MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT Canada NewsWire DENVER , Dec. 9, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engin...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closing Under Share Subscription Agreement

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. In connection with its previously announced common share ...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closes Share Subscription Agreement

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has filed a shel...
MYCOF - Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly addre...

MYCOF - Mydecine Innovations Group GAAP EPS of -$0.35

Mydecine Innovations Group press release ( OTCPK:MYCOF ): Q3 GAAP EPS of -$0.35. The company had $0.08M in cash and cash equivalents as of September 30, 2022. For further details see: Mydecine Innovations Group GAAP EPS of -$0.35

MYCOF - Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial result...
MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that, in connection with its...

MYCOF - MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO Canada NewsWire DENVER , Sept. 23, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ...

MYCOF - InvestorNewsBreaks - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes First Tranche Under Subscription Agreement

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
Previous 10 Next 10